1. Home
  2. KOPN vs LUNG Comparison

KOPN vs LUNG Comparison

Compare KOPN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$2.30

Market Cap

424.9M

Sector

Technology

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.32

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOPN
LUNG
Founded
1984
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Industrial Specialties
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
424.9M
63.6M
IPO Year
1992
2020

Fundamental Metrics

Financial Performance
Metric
KOPN
LUNG
Price
$2.30
$2.32
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
$4.25
$6.81
AVG Volume (30 Days)
3.2M
985.7K
Earning Date
11-12-2025
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$45,602,295.00
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
$43.37
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
3.02
15.59
52 Week Low
$0.71
$1.31
52 Week High
$4.16
$9.37

Technical Indicators

Market Signals
Indicator
KOPN
LUNG
Relative Strength Index (RSI) 40.51 55.38
Support Level $2.32 $2.17
Resistance Level $2.44 $2.30
Average True Range (ATR) 0.17 0.16
MACD -0.01 -0.04
Stochastic Oscillator 1.79 28.00

Price Performance

Historical Comparison
KOPN
LUNG

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: